Recruiting

Testing a new immunotherapy drug combined with chemotherapy for early breast cancer

Plain-English translation of NCT06781281 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This trial is testing , a new immunotherapy medication, when combined with two standard chemotherapy drugs (albumin paclitaxel and epirubicin) given before surgery for early-stage hormone receptor-positive, HER2-negative breast cancer. Some participants will receive the chemotherapy alone, while others will receive the same chemotherapy plus . The goal is to see if adding this medication helps shrink tumors more effectively before surgery.

Studies of similar immunotherapy drugs have shown promise in improving how well chemotherapy works for this type of breast cancer, but more research is needed to confirm whether this new medication provides real benefits for patients while remaining safe.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with early-stage hormone receptor-positive, HER2-negative invasive breast cancer that has not spread to distant sites
your cancer is large enough to be measured on imaging (ultrasound, mammogram, or MRI) and involves lymph nodes or extends beyond the breast
your heart function is normal (ejection fraction of 55% or higher)
you have good overall health and are able to handle chemotherapy
you have not received any prior chemotherapy, radiation, or immunotherapy for this cancer

You likely don't qualify if…

your cancer has spread to other parts of your body (metastatic disease)
you have received any prior chemotherapy, immunotherapy, targeted therapy, or radiation for this cancer
you have a weakened immune system, active hepatitis B or C, or an autoimmune disease
you have serious heart or lung disease
you are pregnant or breastfeeding

What participation looks like

If you join this study, you will receive intravenous (IV) chemotherapy infusions once every three weeks for six cycles (about 18 weeks total). Depending on which group you're assigned to, you may also receive the new immunotherapy medication on day 3 of each cycle. Throughout the study, you will have regular blood tests, heart function checks, and imaging scans to monitor how well the treatment is working and to watch for any side effects. After completing the chemotherapy, you will proceed to surgery as planned.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(1 site)

China

Henan cancer hospital, Zhengzhou